NSABP Foundation
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, NSABP Foundation sits in the top decile of US sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count).
NSABP Foundation: 44 sponsored US clinical trials, 1 recruiting.
NSABP Foundation sponsors 44 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 33 completed. 20 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.
Top-decile sponsor footprint
NSABP Foundation ranks in the top decile of sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
33 of 40 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
44 total, page 1 of 1
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
NCT07058012
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
NCT01872975
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
NCT00382070
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NCT03628066
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
NCT03102047
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
NCT03007407
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
NCT02664077
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
NCT02296801
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
NCT02236000
NSABP Patient Registry and Biospecimen Profiling Repository
NCT01793805
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NCT01705691
Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer
NCT01399359
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
NCT01423123
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
NCT01008150
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
NCT01189227
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
NCT01011478
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
NCT00803647
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00887536
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
NCT00464646
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer
NCT00089323
Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers
NCT00410579
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
NCT00365417
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
NCT00321828
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
NCT00314353
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
NCT00268463
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer
NCT00110695
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
NCT00103181
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
NCT00093795
Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer
NCT00087256
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
NCT00087178
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
NCT00052169
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
NCT00053898
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
NCT00378313
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
NCT00016432
Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer
NCT00009945
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
NCT00004067
Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer
NCT00003830
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
NCT00003906
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
NCT00003782
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00003352
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
NCT00002967
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
NCT00002707
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 16 |
| Phase 3 | 20 |
Therapeutic Areas
What is open in the NSABP Foundation pipeline
1 recruiting of 44 indexed (2% open); 33 completed (75%).
Phase mix: 20 late (III/IV) vs 18 early (I/II) (balanced across stages).
Top condition: Breast Cancer (9 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NSABP Foundation: open-pipeline peers nationwide
Peers matched on 44 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
NSABP Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 44 trials (± recruiting share)
- Agios Pharmaceuticals · 44 trials · 7% recruiting
- Beth Israel Medical Center · 44 trials · 0% recruiting
- Innovative Medical · 44 trials · 0% recruiting
- Kowa Research Institute · 44 trials · 0% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Cumberland Pharmaceuticals · 2% recruiting · 43 trials
- Baxter Healthcare Corporation · 2% recruiting · 46 trials
- Centers for Disease Control and Prevention · 2% recruiting · 139 trials
- USDA, Western Human Nutrition Research Center · 2% recruiting · 47 trials
Related
What to do with this NSABP Foundation page
44 registered trials is a research-attention snapshot, not an endorsement of NSABP Foundation or any single study.
- 1 of NSABP Foundation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition NSABP Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NSABP Foundation pipeline card: 44 registered trials from official public datasets.Report a data error.